Wai Shun

Wai Shun (HK) Pharmaceutical Co., Limited is a prominent pharmaceutical entity and a wholly-owned subsidiary of Grand Pharmaceutical Group Limited. The company serves as the primary international investment and licensing arm for its parent organization, focusing on acquiring high-value biotech assets for the Greater China market. Wai Shun is particularly recognized for its strategic expansion into the radiopharmaceutical sector, having secured exclusive rights to several late-stage diagnostic and therapeutic candidates through partnerships with firms like Telix Pharmaceuticals and ITM. Its portfolio spans oncology, precision intervention, and cardiovascular health, utilizing a range of modalities including radiopharmaceuticals and gene therapies. By integrating global innovation with local manufacturing and commercial expertise, Wai Shun facilitates the delivery of advanced medical solutions to patients in Asia.